149 results about "Atherosclerosis aorta" patented technology

Methods and compositions for inducing long-term tolerance by hybrid nanoparticles are provided. Compositions and formulations comprising hybrid nanoparticles with inherent affinity for innate immune cells are provided.

An ultrasound imaging system for guiding a user to acquire ultrasound image data sets that can be analyzed for the presence of atherosclerosis. In one embodiment, the processor is programmed to analyze ultrasound image data for a vessel of interest and to control a user interface that suggests how an operator should move a transducer to acquire ultrasound image data with the vessel of interest in a desired location. The processor stores multiple ultrasound image data sets taken along a length of the vessel of interest to be analyzed for the presence of an atheroma.

The invention discloses application of lobetyolin in preparation of a medicine for treating atherosclerosis, and belongs to the field of biological medicine. The atherosclerosis comprises atherosclerosis induced by a high methionine diet. Through verification, IL-33 in aortic tissues of ApoE <- / -> mice with high methionine diet is remarkably increased, and the expression level of IL-33 in the aortic tissues of the mice is remarkably reduced compared with that of a model group after the mice are treated by lobetyolin. It is proved that lobetyolin has a positive regulation effect on treatment of atherosclerosis. Through molecular docking analysis, the binding energy between the lobetyolin and the IL-33 is-7.3 kcal / mol, which indicates that the IL-33 and the lobetyolin have good binding stability. The invention provides a new idea for clinical treatment of atherosclerosis.

The invention discloses a scorpion antiatherosclerosis polypeptide and application thereof, and belongs to the technical field of traditional Chinese medicinal material polypeptides. The anti-atherosclerosis polypeptide of the Buthus martensii Karsch is one of a peptide fragment 1, a peptide fragment 2, a peptide fragment 3, a peptide fragment 4, a peptide fragment 5, a peptide fragment 6 and a peptide fragment 7, and the amino acid sequences are respectively shown as SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6 and SEQ ID NO.7. The anti-atherosclerosis polypeptide of the Buthus martensii Karsch is an anti-atherosclerosis polypeptide of the Buthus martensii Karsch. The anti-atherosclerosis polypeptide obtained by screening can significantly reduce oxidative damage and reduce lipid deposition, especially peptide fragment 5; a theoretical basis is provided for medicinal development of the scorpion antiatherosclerosis peptide, and a potential antiatherosclerosis mechanism of the scorpion antiatherosclerosis peptide is disclosed.

The invention discloses application of macrophage exosome molecules induced by fusobacterium nucleatum, and belongs to the technical field of molecular biology. The nucleotide sequence of the macrophage exosome molecule induced by fusobacterium nucleatum is 5 '-ACUGGCUAGGGAAAAUGAUUGGAU-3', and the macrophage exosome molecule can be applied to preparation of a preparation for inducing VSMC cells to be converted into macrophage-like phenotypes, can regulate and control the atherosclerosis process, and provides a new thought and theoretical basis for further research of exosome in the atherosclerosis progress process.

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

Provided are a Lactobacillus plantarum strain, Lactobacillus plantarum PDG8, and a composition thereof. Also provided are methods using Lactobacillus plantarum PDG8 or a composition thereof for treating a cardiovascular disease such as atherosclerosis.

Triphenylphosphonium hydroxytyrosol TPP-HT, its synthesis method and application in the preparation of drugs for improving aortic endothelial cell function. TPP-HT can significantly increase the reduction of human aortic endothelial cell activity caused by saturated fatty acids, inhibit the inflammatory response and oxidative stress caused by saturated fatty acids, and at the same time increase the synthesis of ATP in vascular endothelial cells and the expression of mitochondrial complex II. By anti-inflammatory and protecting mitochondrial function, it can prevent the occurrence and development of atherosclerosis. Therefore, TPP-HT has good application prospects in preventing cardiovascular diseases such as atherosclerosis caused by high-fat-induced endothelial damage, opening up a new medical approach for preventing a series of problems of cardiovascular diseases such as atherosclerosis caused by endothelial damage due to unbalanced dietary structure, and providing a new basis for the development of new drugs.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an active oxygen responsive nano composition and a preparation method thereof. The nano composition is prepared from dilinoleoyl phosphatidyl ethanolamine (DOPE), distearoyl phosphatidyl ethanolamine-ketal thiol-polyethylene glycol (DSPE-TK-PEG), cholesterol, rhein and cerium oxide (CeO2), and is characterized in that the nano composition is prepared from dilinoleoyl phosphatidyl ethanolamine, distearoyl phosphatidyl ethanolamine-ketal thiol-polyethylene glycol (DSPE-TK-PEG), compared with the prior art, the nano composition disclosed by the invention is uniform in particle size, simple in preparation process and high in drug loading capacity, an insoluble drug rhein and an insoluble inorganic substance cerium oxide can be loaded at the same time, and targeted and positioned release of rhein and CeO2 is realized through active oxygen response; the method is a potential new strategy for treating inflammation-based atherosclerosis.

The present invention relates to pharmaceutical composition(s) comprising particles comprising one or more compounds which are inhibitors of microsomal triglyceride transfer protein and / or apolipoprotein B (Apo B) secretion, wherein at least 50% of the particles are characterized by a volume particle fraction less than 10 μm, more preferably less than 5 μm, more preferably less than 2.5 μm. The pharmaceutical composition can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.

The invention discloses a traditional Chinese medicine composition for preventing and treating atherosclerosis and plaque formation and application thereof. The traditional Chinese medicine composition comprises the following traditional Chinese medicine components in parts by weight: 10-15 parts of peach kernel, 7-12 parts of safflower, 12-18 parts of angelica sinensis, 15-25 parts of radix rehmanniae, 12-18 parts of ligusticum wallichii, 10-15 parts of radix paeoniae rubra, 12-18 parts of radix cyathulae, 12-18 parts of platycodon grandiflorum, 12-18 parts of radix bupleuri, 10-15 parts of bran-fried fructus aurantii, 4-8 parts of honey-fried licorice root, 10-15 parts of ginseng, 8-12 parts of poria cocos, 4-8 parts of rhizoma zingiberis, 10-15 parts of rhizoma cyperi, 12-18 parts of radix curcumae, 10-15 parts of cortex albiziae, 12-18 parts of rhizoma pinelliae preparata, 12-18 parts of exocarpium citri grandis, 20-30 parts of 25 parts of allium macrostemon, 25-35 parts of corn stigma, 15-25 parts of plantain herb and 25-35 parts of oyster; based on the theory of traditional Chinese medicine, all traditional Chinese medicine raw materials are screened, and through the combined action of all the raw materials, the traditional Chinese medicine composition has a remarkable curative effect on atherosclerosis and takes effect quickly.

The invention discloses a medicinal moxa composition for preventing and treating atherosclerosis and suppurative bacterial infection co-disease. The medicinal moxa composition comprises coptis chinensis, radix rehmanniae, polygala tenuifolia, juncus effuses and moxa. The medicinal folium artemisiae argyi composition disclosed by the invention can be used for effectively preventing and treating atherosclerosis and skin suppurative bacterial infection co-diseases through a multi-target synergistic effect. The medicinal moxa composition has the core effects of clearing away heart-fire, inducing diuresis for treating stranguria and promoting blood circulation to remove meridian obstruction, and forms a complete treatment system which uses cold and warm as well as treats both symptoms and root causes by purging fire for removing toxin through coptis chinensis, clearing heat and cooling blood through radix rehmanniae, soothing nerves and promoting intelligence through polygala, inducing diuresis and conducting heat downward movement through juncus effuses and combining moxa floss for warming and dredging meridians, eliminating cold to stop pain, resisting bacteria and diminishing inflammation. By inhibiting inflammatory factors, regulating epithelial cell proliferation and reaction to oxidative stress, regulating fluid shear force, atherosclerosis and Kaposi sarcoma-related herpesvirus infection-related pathways and other mechanisms, the medicinal folium artemisiae argyi composition realizes synergistic prevention and treatment of atherosclerosis and skin infection, and provides a basis for co-disease treatment.

The invention discloses a preparation method and device of a cocoa product with a cardiovascular function improving function, and belongs to the technical field of food processing. Dry cocoa beans and blueberry berries are used as raw materials, the dry cocoa beans are crushed and sieved and then mixed with deionized water to extract cocoa butter, then the cocoa butter is mixed with wall-broken blueberry homogenate, the deionized water is used as a guiding agent to aggregate reaction components, cells are completely broken through a three-layer stepped reaction layer, and the cocoa butter is obtained. The dissolution of cocoa butter in the cocoa beans and active substances in the blueberries is promoted; the whole reaction device and the conveying pipeline are negative-pressure and oxygen-free, so that the stability of active substances is ensured. The cocoa product obtained by adopting the device and the method disclosed by the invention is fine and smooth in taste, melts in the mouth, is basically free from greasy feeling and granular feeling, perfectly retains the special flavors of cocoa beans and blueberries, is rich in cocoa butter and anthocyanin substances, and has relatively strong effects of preventing atherosclerosis and improving cardiovascular.

Compositions and methods for treating rheumatoid arthritis and / or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.

The invention belongs to the technical field of animal model construction, and particularly relates to a method for constructing a silicosis-related atherosclerosis animal model. Comprising the following steps: after adaptive feeding of healthy mice, intragastric ursodeoxycholic acid is performed once, the mice are fed with high-fat feed and periodically subjected to nasal drop treatment by 50mg / mL SiO2 suspension for more than 10 weeks, and during the period, the mice freely eat and drink water; wherein the specific operation of the periodic 50mg / mL SiO2 suspension nasal drop is as follows: the periodic 50mg / mL SiO2 suspension nasal drop is carried out once every 3-4 days, and 30-50mu L of the periodic 50mg / mL SiO2 suspension nasal drop is taken each time; the intragastric administration dosage of ursodeoxycholic acid is that 100-200 mg of ursodeoxycholic acid is administered to each kilogram of mouse body weight. According to the invention, a triple induction strategy of silicon dioxide exposure, high fat diet and induction factor stimulation is adopted, two pathological characteristics of silicosis and atherosclerosis can be successfully and stably generated in a C57BL / 6J mouse, and relevance of silicosis and atherosclerosis can be simulated at the same time.

The invention discloses an application of an NRF2 signal channel activator in preparation of a medicine for preventing or treating hyperuricemia-related atherosclerosis, relates to the technical field of medicines, and particularly relates to an application of the NRF2 signal channel activator in preparation of a medicine for preventing or treating hyperuricemia-related atherosclerosis. The NRF2 signal channel activator is used for up-regulating NRF2 protein expression or enhancing transcriptional activity of the NRF2 protein; the NRF2 signal channel activator is used for up-regulating expression of a downstream target gene SLC7A11 and / or GPX4 so as to inhibit ferroptosis of hyperuricemia aortic macrophages; the level of glutathione (GSH) in serum is increased; the malondialdehyde (MDA) and / or iron ion (Fe < 2 + >) level in serum is reduced; nRF2 signal channel activation and macrophage ferroptosis inhibition are associated, and the NRF2 signal channel is applied to prevention and treatment medicines for hyperuricemia-related atherosclerosis, so that development of specific treatment medicines for patients suffering from hyperuricemia-related atherosclerosis is facilitated.

The invention relates to the field of pharmaceutical compositions for promoting atherosclerosis, in particular to a lipid oxide-AGEs composite pharmaceutical composition for promoting atherosclerosis, a method for constructing a rat coronary heart disease ischemia reperfusion injury model by using the composition and application of the composition. The composition comprises 80-90 parts of oxidized lipid, 4-6 parts of 7-ketocholesterol, 2-4 parts of 25-hydroxycholesterol, 8-10 parts of trans-fatty acid, 200-300 parts of an advanced glycosylation end product, 180-220 parts of casein, 320-360 parts of cane sugar, 145-165 parts of corn starch, 45-55 parts of cellulose, 30-40 parts of a mineral mixture, 8-12 parts of a vitamin mixture and 0.4-0.6 mg / kg of folic acid, the vitamin B6 is 1.8 to 2.2 mg / kg, and the vitamin B12 is 0.007 to 0.009 mg / kg.

The invention relates to the field of biological medicine, and discloses application of SCAP as a target spot in treatment or prevention of atherosclerosis. The invention proves that compared with normal control, SCAP expression of macrophages in aortic tissues of atherosclerosis patients is up-regulated. The invention proves that the progress of atherosclerosis can be obviously relieved by macrophage SCAP specific knockout. The invention also proves that macrophage SCAP specific knockout can improve aortic plaque lipid accumulation, and the local inflammation level is improved by influencing macrophage polarization to relieve atherosclerosis. According to the application, the application of the macrophage SCAP as a new target spot in treating or preventing the atherosclerosis is found.

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain H-APPAMP compounds (referred to herein as “H-APPAMP compounds”) that, inter alia, inhibit cyclin-dependent protein kinases (CDKs), especially CDK12 and / or CDK13, and are selective, for example, for CDK12 and / or CDK13 as compared to CDK7. In addition to selectively inhibiting CDK12 and / or CDK13, the compounds also act as selective Cyclin K degraders thereby removing the key signaling mechanism required for CDK12 and / or CDK13 activation; this confers additional cellular potency and selectivity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK, especially CDK12 and / or CDK13; and to treat disorders including: disorders that are associated with CDK, especially CDK12 and / or CDK13; disorders that result from an inappropriate activity of a CDK, especially CDK12 and / or CDK13; disorders that are associated with CDK mutation, especially CDK12 and / or CDK13 mutation; disorders that are associated with CDK overexpression, especially CDK12 and / or CDK13 overexpression; disorders that are associated with upstream pathway activation of CDK, especially CDK12 and / or CDK13; disorders that are ameliorated by the inhibition of CDK, especially CDK12 and / or CDK13; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; cardiovascular disorders (including atherosclerosis); autoimmune disorders (including rheumatoid arthritis); and disorders caused by dysfunction of translation in cells (including muscular dystrophy). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti estrogen, an anti-androgen, a Her2 blocker, a cytotoxic chemotherapeutic agent, an agent stimulating the immune system, a checkpoint inhibitor, a DNA repair inhibitor, etc.

The present application relates to a kind of construction method of atherosclerosis humanized mouse model, belong to genetic engineering and genetic modification technical field.The present application is first in ApoE and Ldlr double gene knockout mouse background and obtains NOD-4G gene knockout mouse by knockouting Prkdc and Il2rg gene in mouse, humanized atherosclerosis model is constructed by injecting human umbilical cord blood CD133+stem cell and high-fat feed feeding.Through to atherosclerosis degree analysis, it is found that the aorta and aortic root of the humanized atherosclerosis model constructed have a large number of plaque formation, and contain human CD45 + Leukocyte.This atherosclerosis humanized mouse model provides better animal genetic model for the analysis of the role of human immune cells in the occurrence and development of atherosclerosis disease, and has important significance for the research of human disease and the development of new therapy.

The present invention provides a kind of magnetic targeting, engineered extracellular vesicle loaded with hepatocyte responsive mRNA and its construction method and application, which belongs to the field of biomedicine technology. A kind of engineered extracellular vesicle, including genetically engineered extracellular vesicles, the surface of which is coupled with transferrin-modified superparamagnetic iron oxide nanoparticles and loaded with an agonist of the pro-apoptotic protein BAX; PTGFRN (Δ687) ‑ MCP fusion protein is expressed on the extracellular vesicle membrane, and MCPRNA binding protein increases the loading capacity of the extracellular vesicle to iBaxmRNA containing miR ‑ 122 recognition site; The agonist of the pro-apoptotic protein BAX is embedded in the phospholipid bilayer of the extracellular vesicle. The preparation method of the engineered extracellular vesicle of the present invention is simple, has the advantages of aortic plaque magnetic targeting, efficient nucleic acid drug loading, low side effects, etc., and provides a reference for the treatment of atherosclerosis and other age-related diseases.

The invention relates to the field of medicine application of organic compounds, in particular to application of hematoxylin A in preparation of medicine for treating atherosclerosis. Animal experiments show that the hematoxylin A can effectively reduce TC, TG and LDL-C levels of AS mouse serum, increase the HDL-C level of AS mouse serum, relieve aortic pathological change and inflammatory cell infiltration of AS mouse, reduce the area of aortic lipid plaque and the area of aortic root lipid plaque of AS mouse, effectively delay the pathological change process of AS mouse, and improve the curative effect of AS mouse. Therefore, the hematoxylin A has a relatively good treatment effect on the atherosclerosis. Therefore, the hematoxylin A can be used for preparing the medicine for treating the atherosclerosis.

The invention relates to the technical field of novel drug application of compounds, in particular to a compound Man-Tz, a biological orthogonal reaction system and application of the compound Man-Tz. The dTRIM24 is accurately released at the atherosclerotic plaque through a biological orthogonal targeting technology, and the problem of non-specific distribution caused by a traditional administration mode is effectively solved by utilizing the specific reaction of an artificial target point Man-Tz and TCO-dTRIM24-TCO. According to the technology, the TRIM24 protein of 117kDa can be specifically degraded, and macrophages are promoted to be polarized to an anti-inflammatory M2 type by inhibiting Stat6 acetylation, so that plaque formation is inhibited. Experiments prove that the system has concentration and time-dependent effects, drug exposure of non-target tissues is remarkably reduced while efficient degradation activity is maintained, and a novel targeted therapy strategy with high specificity and low toxic and side effects is provided for atherosclerosis treatment.

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition and a preparation method and application thereof. The traditional Chinese medicine composition provided by the invention comprises astragalus membranaceus, cinnamon, semen cassiae, lotus leaves, poria cocos, lophatherum gracile, malt, hawthorn, rose, pogostemon cablin, sophora flower, semen torreya and emblic leafflower fruit. The formula takes the effects of tonifying spleen and promoting diuresis, soothing liver and regulating qi, and removing food retention and dissolving turbidity as the core, and has multiple effects of promoting urination and relieving stasis. The traditional Chinese medicine composition provided by the invention can regulate and control abnormal signal pathways of fatty liver and atherosclerosis; the compound has no obvious inhibition effect on a hepatic cell line HepG2 and has an inhibition effect on a hepatic stellate cell line LX2; the obvious lipid-lowering effect is achieved on a HepG2 high-lipid model; liver fat accumulation and liver injury in a TAA-induced zebrafish fatty liver model can be remarkably improved.

The present invention refers to Annexin A8 (AnxA8) inhibitors, or pharmaceutical composition comprising thereof, for use in a method for the treatment and / or prevention of atherosclerosis. Preferably, the method comprises preventing atherosclerotic plaque formation.

The present application relates to the field of food, health care products and medicine, and specifically relates to a purslane oral composition for regulating blood lipid and resisting atherosclerosis, and a preparation method and application thereof. The present application takes purslane extract, galangal extract and borneol as core components, and realizes the synergistic effects of lipid regulation, anti-inflammation, reduction of plaque area, stabilization of vulnerable plaque, mild anti-thrombus and myocardial protection through scientific proportioning. The bioavailability is significantly improved by combining the tongue sublingual absorption of borneol and the mucosal penetration of galangal volatile oil. The composition has comprehensive targets, definite effects and good safety, and can be made into oral dosage forms such as buccal tablets, dripping pills and oral disintegrating tablets, and is suitable for daily oral care of cardiovascular sub-healthy people.

The invention provides an anti-atherosclerosis lipidosome carrier drug and a preparation method thereof, and belongs to the technical field of biological pharmacy, the lipidosome carrier drug is prepared by taking tussah peptide, premna microphylla leaf flavonoid glycoside, clausena lansium leaf polysaccharide and troxerutin as active ingredients. The antheraea pernyi peptide is a product between 1kDa and 5kDa obtained by extracting protein from antheraea pernyi and sequentially carrying out enzymolysis by bacillus subtilis protease and pepsin. The premna microphylla leaf flavonoid glycoside is prepared by performing enzymolysis and water extraction on premna microphylla leaves and then purifying the premna microphylla leaves through an HPD-600 macroporous adsorption resin column. The clausena lansium leaf polysaccharide is prepared by the following steps: extracting clausena lansium leaves with water, precipitating with ethanol, redissolving, and purifying through a DEAE-52 cellulose column and a Sephadex G-100 gel column in sequence. All the components aim at key pathological links of atherosclerosis respectively, and the core advantages of high efficiency, safety and stability are achieved through multi-component synergistic compatibility and closed-loop optimization of a fine preparation process.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of LGR5 in diagnosis and treatment of vascular calcification. Experiments prove that the key effect of the LGR5 in aortic smooth muscle calcification is found for the first time, it is indicated that the LGR5 is a new target spot for regulating and controlling vascular calcification, meanwhile, vascular calcification can be accurately inhibited through knockdown / knockout of the specific Lgr5 gene of vascular smooth muscle, and meanwhile, vascular calcification can be accurately inhibited through knockout / knockout of the specific Lgr5 gene of the vascular smooth muscle. According to the application disclosed by the invention, the mechanism that the Lgr5 regulates and controls the osteogenic differentiation of the vascular smooth muscle cells through the Wnt / beta-catenin signal channel is preliminarily clarified, and a clear action target and a theoretical basis are provided for drug research and development; the invention provides a new strategy for treatment of diseases such as atherosclerosis and the like, and has a wide clinical application prospect.

The invention relates to an F base modified von Willebrand factor vWF targeting aptamer and an application of the F base modified von Willebrand factor vWF targeting aptamer. Specifically, the invention provides an F base modified vWF targeting aptamer (AF-BT100), the F base modified vWF targeting aptamer comprises a nucleotide core sequence as shown in SEQ ID NO: 1, and the 5'end and the 3 'end are respectively connected with at least two artificial hydrophobic F bases. The invention also comprises a radionuclide-labeled molecular imaging probe [68Ga] Ga-NOTA-AF-BT100, which can realize specific PET imaging in the focus of atherosclerosis, carotid artery thrombosis and acute myocardial infarction. According to the invention, the integrated application of diagnosis and treatment of the pantovascular diseases based on the same vWF targeting aptamer is realized for the first time, and a new strategy is provided for accurate diagnosis and treatment of the pantovascular diseases.